In short
There is currently 1 ongoing clinical trial investigating treatments for allergic respiratory disease, specifically focusing on allergic rhinitis caused by dog allergies. The trial is being conducted in Sweden and tests an allergen immunotherapy treatment called Alutard SQ dog, which aims to reduce allergic symptoms through regular injections over one year.
Clinical trial locations
Evaluation of Alutard SQ dog allergen immunotherapy in patients with allergic rhinitis due to dog allergy - A one-year study in Swedish practice
This trial is investigating how well Alutard SQ dog treatment works for people who suffer from allergic rhinitis caused by dog allergies. The treatment involves receiving regular injections under the skin that contain small amounts of dog allergens. The goal is to help the body gradually build tolerance to these allergens, reducing symptoms such as sneezing, runny nose, itchy eyes, and breathing difficulties when exposed to dogs.
Main inclusion criteria:
- Adults aged between 18 and 50 years
- Moderate to severe allergic symptoms when exposed to dogs
- Determined suitable for Alutard SQ Dog treatment by a doctor
- Written consent to participate in the trial
- Women who can become pregnant must use effective birth control and have a negative pregnancy test before starting
Main exclusion criteria:
- Age below 18 or above 65 years
- Previous treatment with allergy shots for dog allergy in the past 5 years
- Pregnancy or planning to become pregnant during the study
- Severe asthma or serious heart or lung conditions
- Current treatment with certain heart and blood pressure medications called beta-blockers
- Active autoimmune diseases or history of severe allergic reactions requiring emergency treatment
- Participation in other clinical trials or inability to follow study procedures
Focus and goal:
The trial aims to evaluate how effective Alutard SQ dog treatment is in improving allergy symptoms after one year of treatment. Participants will receive regular injections and may also use additional medications like Nasonex nasal spray, Livostin eye drops, and Desloratadine tablets to help manage symptoms. Researchers will measure improvements by tracking nasal symptoms, eye symptoms, and breathing ability throughout the year-long treatment period. They will also conduct blood tests to measure antibody levels related to dog allergies.
Investigational drug:
Alutard SQ dog is an allergen immunotherapy medication that works by gradually exposing patients to small amounts of dog allergens through injections. Over time, this helps the immune system become less sensitive to these allergens, potentially reducing symptoms like sneezing, runny nose, itchy eyes, and breathing difficulties when exposed to dogs. The treatment is administered through subcutaneous injections over an extended period to build up tolerance.
Summary
Currently, there is one active clinical trial for allergic respiratory disease, specifically targeting allergic rhinitis caused by dog allergies. This trial is being conducted in Sweden and focuses on testing Alutard SQ dog allergen immunotherapy. The study represents an important investigation into allergen-specific treatments that aim to modify the body's immune response rather than simply managing symptoms. The trial involves a year-long treatment period with regular monitoring of symptoms and immune responses. While only one trial is currently ongoing in this specific area, it provides an opportunity for patients in Sweden who meet the eligibility criteria and suffer from moderate to severe dog allergies to explore this treatment approach under medical supervision.
